Acura Pharmaceuticals, Inc. (ACUR)

Acura Pharmaceuticals Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Year Ending	Current	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
Market Capitalization	1	-	28	7	6	2
Market Cap Growth	-	-	318.44%	10.44%	152.94%	-62.17%
Enterprise Value	-	-	28	13	11	7
PE Ratio	-	0	-26.32	-4.09	-1.56	-0.63
PS Ratio	-	-	18.17	1.90	2.31	5.93
PB Ratio	0	0	159.55	-1.15	-1.30	-0.67
P/FCF Ratio	-	-	-38.28	-9.44	-9.94	-0.62
P/OCF Ratio	-	-	-38.28	-9.44	-9.94	-0.62
EV/Sales Ratio	-	-	18.22	3.54	4.25	16.01
EV/EBITDA Ratio	-	-	-23.46	-19.97	-15.56	-1.81
EV/EBIT Ratio	-	-	-21.84	-16.68	-11.31	-1.68
EV/FCF Ratio	-	-	-38.39	-17.58	-18.26	-1.68
Debt / Equity Ratio	0	0	1.03	-1.06	-1.27	-1.17
Debt / EBITDA Ratio	-	-	-0.12	-9.90	-8.28	-1.17
Debt / FCF Ratio	-	-	-0.20	-8.72	-9.71	-1.08
Quick Ratio	0	0	0.43	0.14	0.98	0.21
Current Ratio	0	0	0.72	0.16	1.10	0.32
Asset Turnover	0	0	1.82	2.06	1.04	0.19
Interest Coverage	0	0	-6.07	-1.68	-1.61	-17.56
Return on Equity (ROE)	-	-	-606.18%	28.14%	83.32%	106.22%
Return on Assets (ROA)	-	-	-125.47%	-95.51%	-154.18%	-178.53%
Return on Capital (ROIC)	-	-	-370.12%	-200.53%	-57.59%	-644.98%
Earnings Yield	-	-3.80%	-24.43%	-64.27%	-158.13%
FCF Yield	0.00%	-2.61%	-10.59%	-10.06%	-160.84%
Buyback Yield / Dilution	-	-75.75%	-20.96%	-26.36%	-32.97%
Total Shareholder Return	-	-75.75%	-20.96%	-26.36%	-32.97%

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.